Table 1. Clinical characteristics and therapy responses of all 253 patients.
| Data (%) | |
|---|---|
| Age (mean ± SD), years | 65.2 ± 12.4 |
| Sex | |
| Male | 104 (41.1) |
| Female | 149 (58.9) |
| DM | |
| Yes | 48 (19.0) |
| No | 205 (81.0) |
| Smoking history | |
| Non-smoker | 172 (68.0) |
| Smoker | 81 (32.0) |
| EGFR mutation a | |
| Common | 228 (90.1) |
| Uncommon | 25 (9.9) |
| No of brain metastases | |
| 0 | 196 (77.5) |
| 1 | 14 (5.5) |
| 2 | 8 (3.2) |
| >2 | 35 (13.8) |
| No of distant metastasis | |
| 0–2 | 215 (85.0) |
| >2 | 38 (15.0) |
| Malignant effusion | |
| Yes | 151 (60.1) |
| No | 102 (39.9) |
| ECOG PS | |
| 0–1 | 206 (81.4) |
| 2–4 | 47 (18.6) |
| Lymphocyte (median ± IQR/mm3) | 1599 ± 903e |
| Lymphocyte at 1 month (median ± IQR /mm3) | 1397 ± 869 |
| Monocyte (median ± IQR /mm3) | 428 ± 279 |
| Monocyte at 1 month (median ± IQR /mm3) | 398 ± 278 |
| LMR (median ± IQR) | 3.6 ± 2.6 |
| LMR at 1 month (median ± IQR) | 3.2 ± 2.7 |
| PFS (median), months | 10.3 |
| OS (median), months | 22.0 |
a Exon 19 deletion and L858R mutations were defined as common mutations. Other mutations or compound mutations were defined as uncommon mutations.
DM, diabetes mellitus; EGFR, epidermal growth factor receptor; ECOG, Eastern Cooperative Oncology Group; PS, performance status; LMR, lymphocyte-to-monocyte ratio; PFS, progression-free survival; OS, overall survival